Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Haluzík

Showing results (1-10 of 113) with videos related to

Pageof 12
Sort By:
Vnitrni Lekarstvi|March 24, 2017
[Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm]Martin Haluzík
Vnitrni Lekarstvi|April 21, 2015
[The treatment of diabetes in patients with liver and renal impairment]Martin Haluzík
Vnitrni Lekarstvi|December 7, 2016
[Bariatric surgeries at diabetic patients]Martin Haluzík
Vnitrni Lekarstvi|October 9, 2014
[News and perspectives in insulin treatment]Martin Haluzík
Vnitrni Lekarstvi|September 18, 2020
Incretin-based treatment of diabetes and cardiovascular complicationsMartin Haluzík
Expert Opinion on Drug Safety|October 13, 2021
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitusPeter Novodvorský, Martin Haluzík
Current Atherosclerosis Reports|January 26, 2022
The Effect of GLP-1 Receptor Agonists on Postprandial LipaemiaPeter Novodvorský, Martin Haluzík
The Journal of Endocrinology|January 7, 2016
The role of bile acids in metabolic regulationLibor Vítek, Martin Haluzík
International Journal of Endocrinology|October 4, 2013
Renal Effects of DPP-4 Inhibitors: A Focus on MicroalbuminuriaMartin Haluzík, Jan Frolík, Ivan Rychlík
Vnitrni Lekarstvi|September 17, 2015
[Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide]Martin Haluzík, Pavel Trachta, Miloš Mráz
Pageof 12

Showing results (1-10 of 113) with videos related to

Sort By:
Pageof 12
Vnitrni Lekarstvi|March 24, 2017
[Long-acting insulins in the treatment of type 2 diabetes and their position in the current treatment algorithm]Martin Haluzík
Vnitrni Lekarstvi|April 21, 2015
[The treatment of diabetes in patients with liver and renal impairment]Martin Haluzík
Vnitrni Lekarstvi|December 7, 2016
[Bariatric surgeries at diabetic patients]Martin Haluzík
Vnitrni Lekarstvi|October 9, 2014
[News and perspectives in insulin treatment]Martin Haluzík
Vnitrni Lekarstvi|September 18, 2020
Incretin-based treatment of diabetes and cardiovascular complicationsMartin Haluzík
Expert Opinion on Drug Safety|October 13, 2021
An update on the safety of insulin-GLP-1 receptor agonist combinations in type 2 diabetes mellitusPeter Novodvorský, Martin Haluzík
Current Atherosclerosis Reports|January 26, 2022
The Effect of GLP-1 Receptor Agonists on Postprandial LipaemiaPeter Novodvorský, Martin Haluzík
The Journal of Endocrinology|January 7, 2016
The role of bile acids in metabolic regulationLibor Vítek, Martin Haluzík
International Journal of Endocrinology|October 4, 2013
Renal Effects of DPP-4 Inhibitors: A Focus on MicroalbuminuriaMartin Haluzík, Jan Frolík, Ivan Rychlík
Vnitrni Lekarstvi|September 17, 2015
[Cardiovascular effects of GLP-1 receptor agonist treatment: focus on liraglutide]Martin Haluzík, Pavel Trachta, Miloš Mráz
Pageof 12